Last reviewed · How we verify
AP or TP
Selective serotonin reuptake inhibitor
Selective serotonin reuptake inhibitor Used for Major depressive disorder.
At a glance
| Generic name | AP or TP |
|---|---|
| Also known as | AP chemotherapy regimen was pemetrexed combined with cisplatin, and TP chemotherapy regimen was paclitaxel combined with cisplatin. |
| Sponsor | Sichuan Baili Pharmaceutical Co., Ltd. |
| Drug class | Selective serotonin reuptake inhibitor |
| Target | Serotonin transporter |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 2 |
Mechanism of action
AP or TP is used to treat depression by increasing serotonin levels in the brain.
Approved indications
- Major depressive disorder
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
- Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients (NA)
- Electro-Acupuncture in Lung cancER : EALER Study (NA)
- SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC. (PHASE2)
- the Gut Microbiome and Metabolomics in Chronic Lower extreMities Threatening Ischemia
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AP or TP CI brief — competitive landscape report
- AP or TP updates RSS · CI watch RSS
- Sichuan Baili Pharmaceutical Co., Ltd. portfolio CI